The FDA approved intravesical mitomycin in non–muscle-invasive bladder cancer as an nonsurgical alternative to transurethral ...

During a live event, John S. Renshaw, MD, and other oncologists discussed various trials of novel regimens for patients with ...

During a live event, Danielle M. Brander, MD, discussed use of zanubrutinib in high-risk chronic lymphocytic leukemia.

The FDA has approved a tablet version of zanubrutinib for all indications, improving convenience and reducing pill burden for ...

The randomized, phase 3 study is enrolling patients with metastatic kidney cancer who are initially treated with an ...

Ghia P, Barr PM, Allan JN, et al. Final analysis of fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in the phase 2 CAPTIVATE study. J Clin ...

Jill Feldman discusses the background of the phase 2 COCOON trial in advanced non–small cell lung cancer with EGFR mutations.

Seven-year follow-up data on over 1400 patients show radium-223's long-term safety, with a low 2% secondary malignancy rate, reflecting real-world use.

Panelists discuss how risk stratification, symptom burden, and splenomegaly guide treatment decisions for a 68-year-old woman with intermediate-risk myelofibrosis who isn’t interested in transplant.

President Donald J. Trump has signaled that lowering the costs of prescription drugs will be a priority for his second term.

Panelists discuss how JAK inhibitor therapy can benefit patients with intermediate-1–risk myelofibrosis despite being studied primarily in higher-risk patients in the COMFORT and JUMP trials.

A panelist discusses how to sequence the four approved cGVHD agents based on patient-specific factors, recommending exotilimab or belumosidil for lung involvement, any of the three oral agents for ...